Tuesday, 15 Oct 2019

PsA/SpA

Datesort ascending Type Title Save
08 Oct 2019 Social Note to Colleague: How can you possibly diagnose and treat ankylosing spondylitis in a patient with polyarthralgias, +B27 but nothing else (no enthesitis, Pso, IBD, Abnl Schobers and neg SI films)?? The diagnosis (poor sleep, tender points) was obvious. You know who you are
07 Oct 2019 News FUTURE 5 - Secukinumab and Less Radiographic Progression in Psoriatic Arthritis
04 Oct 2019 Social Claims study of RA, PsA, AS/SpA patients on TNF inhibitors shows a comparison of 31,527 MTX vs 34,651 TNFi initiators. MTX was D/C sooner in PsA & AS [aHR 1.10, 1.23) vs RA pts. Concomitant MTX reduced risk of TNFi D/C in all [aHR 0.85, 0.81, 0.79] https://t.co/0l2J2FDsUm
02 Oct 2019 News Ixekizumab vs. Adalimumab in Psoriatic Arthritis
30 Sep 2019 Social Tofacitinib therapy is being studied (not yet approved) in several dermatologic conditions - psoriasis, alopecia areata/universalis, vitiligo, atopic dermatitis and dermatomyositis. https://t.co/Ez3u95Eh7K
22 Sep 2019 Social Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
19 Sep 2019 News NSAID Use Linked With Hypertension in Ankylosing Spondylitis
19 Sep 2019 Social Prospective ankylosing spondylitis cohort - 628 without HTN F/U x12 mos; 200 Rx w/ NSAIDs; of these 129 developed incident HTN. NSAID use associated with incr risk of HTN (HR 1.12; CI, 1.04‐1.20), not effected by age, biologics, dz activity https://t.co/T6y5OcCgMM
18 Sep 2019 Social Novartis announced 16 wk results from the PREVENT trial - secukinumab shown to have superior ASAS40 responses in active non-radiographic axial spondyloarthritis (nr-axSpA). They estimate there are 1.7 million with nr-axSpA in the EU and US. https://t.co/IamZNN7Itc
17 Sep 2019 Social Review of 927 PSUMMIT PsA patients treated with Ustekinumab shows IL- 17A, IL- 17F & IL-23 correlated with baseline skin scores (r=0.26-0.62), but not joint or disease activity scores. No biomarker (IL- 17A/F, IL- 23, CRP) predicted ustekinumab responses https://t.co/JORFZj6QgJ
13 Sep 2019 Social TICOPA study was a T2T strategy trial in psoriatic arthritis to improve outcomes. 5 yr outcomes of 110 pts shows simlar low Dz activity in TC 69% vs SOC 76%. Biologic use was higher in TC ( 33%). Not much advantage to TC - just more biologics and less MTX https://t.co/3D890Z8bSS
12 Sep 2019 Social Study of the Taiwan National Health Insurance database shows that ankylosing spondylitis patients may have a higher risk of diabetes (IRR 1.21) compared to non-AS group (1.43 vs 1.19 per 100 person-years, 95% CI 1.02 to 1.43, p=0.025). https://t.co/71EfDtwK2g
09 Sep 2019 Social RheumNow Podcast is up - Do’s and Don’ts in Spondylitis (9.5.19). View it here>> https://t.co/OU9mAdO4Iw or listen to the Podcast on iTunes or SoundCloud>> https://t.co/TiBevXDyAH
09 Sep 2019 News Anti-IL-23 Beats IL-17 in Plaque Psoriasis
06 Sep 2019 Social A systematic review of mental health issues in #PsA shows that psoriatic arthritis patients have high prevalence of Anxiety - 33% have mild anxiety & 21% moderate. Depression is mild in 20% & 14% have moderate depression. Pain is worse with both. https://t.co/XU1HVDlVal
29 Aug 2019 Social Amgen Inc will buy Celgene Corp’s psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year. https://t.co/0DkfUG5alt
27 Aug 2019 News Taltz FDA Approved for Ankylosing Spondylitis (Radiographic Axial SpA)
26 Aug 2019 News ACR/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
26 Aug 2019 Social FDA has approved Taltz (ixekizumab) use in Active Ankylosing Spondylitis (Axial Spondyloarthritis). IXE previously approved for psoriasis & PsA. Recommended dose is 160 mg SC (two 80 mg injections) at Week 0, followed by 80 mg every 4 weeks. https://t.co/S8zwuYuK2H
23 Aug 2019 Social European Study of 24,195 axSpA pts shows that 1st TNFi resulted in 27% ASDAS inactive disease @6 months & 59% achieved BASDAI <40; 80% continued Rx after 1 year. 1178 patients w/ non-radiographic axSpA had lower 12-mos retention (73%) https://t.co/KJn5eD6wWw